Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life

被引:2
|
作者
Farooq, Juveriya [1 ,2 ]
Sana, M. M.
Chetana, P. M. [1 ]
Almuqbil, Mansour [3 ]
Bhat, Nagapati Prabhakar [2 ]
Sultana, Rokeya [4 ]
Khaiser, UmaimaFarheen [5 ]
Asdaq, Syed Mohammed Basheeruddin [6 ]
Almalki, Mutlaq Eidhah M. [7 ]
Khormi, Amro Mohammed Sawadi [6 ,7 ]
Albraiki, Salem Ahmad [8 ]
Almadani, Moneer E. [9 ]
机构
[1] Shree Devi Coll Pharm, Dept Pharm Practice, Mangalore 574142, Karnataka, India
[2] Yenepoya Deemed Univ, Dept Pharmacol, Deralakatte 575018, Karnataka, India
[3] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh 11451, Saudi Arabia
[4] Yenepoya Deemed Univ, Yenepoya Pharm Coll & Res Ctr, Dept Pharmacognosy, Deralakatte 575018, Karnataka, India
[5] Yenepoya Deemed Univ, Yenepoya Pharm Coll & Res Ctr, Dept Pharm Practice, Deralakatte 575018, Karnataka, India
[6] AlMaarefa Univ, Coll Pharm, Dept Pharm Practice, Riyadh 13713, Saudi Arabia
[7] King Saud Univ Med City, Riyadh, Saudi Arabia
[8] King Abdul Aziz Med City, Dept Pharm, Riyadh, Saudi Arabia
[9] AlMaarefa Univ, Coll Med, Dept Clin Med, Riyadh 13713, Saudi Arabia
关键词
Polypharmacy; Drug-drug interaction; Chronic liver disease; Cirrhosis; Quality of life; BETA-BLOCKERS; CIRRHOSIS; QUESTIONNAIRE;
D O I
10.1016/j.jsps.2023.06.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple prescriptions for different medications may be needed for chronic conditions, increasing the risk of polypharmacy. The WHO defined polypharmacy as ''the administration of many drugs at the same time or the administration of an excessive number of drugs". The primary goal of this study was to evaluate polypharmacy in patients with chronic liver disease and to identify potential drug-drug interactions associated with it. A cross-sectional study was conducted at a tertiary care hospital in Mangalore, Karnataka, for six months, from November 2020 to April 2021. The study involved 118 patients with chronic liver disease from various age groups. Data was gathered by analyzing patients' medical records kept on the ward and interviewing them individually. In admission and discharge prescriptions, polypharmacy was examined. Online interaction checkers from Drugs.com and Medscape were used to interpret potential drug-drug interactions. The SF-36 and Chronic Liver Disease Questionnaire were used to measure the quality of life. The data obtained were analyzed statistically to determine the significant correlation. The number of prescribed drugs was significantly correlated (P = 0.018) with the severity of liver disease in Child-Pugh categories B and C. Additionally, moderate polypharmacy reduced quality of life (P < 0.05), and the physical health category was significantly associated with disease severity (P < 0.05). Drug-drug interactions were found in 108 out of the 118 examined prescriptions, totaling 586 interactions in the admission list and 405 interactions in the discharge list. If the potentially serious main drug interaction identified in this study is not well monitored, it could lead to a serious, potentially fatal health condition. Despite being advised, safety is not always guaranteed by liver enzyme monitoring. Therefore, healthcare providers must take additional precautions to avoid inappropriate prescribing, minimize side effects, and ensure drug safety.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Polypharmacy in hospice patients - current situation, threats associated with adverse effects and drug-drug interactions and therapeutical implications
    Kotlinska-Lemieszek, Aleksandra
    Zaporowska-Stachowiak, Iwona
    MEDYCYNA PALIATYWNA-PALLIATIVE MEDICINE, 2013, 5 (03): : 79 - 87
  • [42] Medication utilization patterns in patients with post-COVID syndrome (PCS): Implications for polypharmacy and drug-drug interactions
    Michael, Henry Ukachukwu
    Brouillette, Marie-Josee
    Fellows, Lesley K.
    Mayo, Nancy E.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2024, 64 (04)
  • [43] INTERACTION BETWEEN LIVER-DISEASE AND CHRONIC DRUG INGESTION ON HEPATIC DRUG-METABOLISM
    FARRELL, GC
    COOKSLEY, WGE
    POWELL, LW
    HART, P
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1977, 4 (05) : 488 - 489
  • [44] INTERACTION BETWEEN LIVER-DISEASE AND CHRONIC DRUG INGESTION ON HEPATIC DRUG-METABOLISM
    FARRELL, GC
    COOKSLEY, WGE
    POWELL, LW
    HART, P
    GASTROENTEROLOGY, 1976, 71 (05) : 905 - 905
  • [46] Severity of liver disease and quality of life in liver transplantation
    Freire de Aguiar, Maria Isis
    Batista Braga, Violante Augusta
    de Almeida, Paulo Cesar
    Parente Garcia, Jose Huygens
    de Lima, Ciebia Azevedo
    ACTA PAULISTA DE ENFERMAGEM, 2016, 29 (01) : 107 - 114
  • [47] A COMPLICATED CASE OF SEROTONIN SYNDROME IN AN ELDERLY PATIENT WITH PREEXISTING POLYPHARMACY AND DRUG-DRUG INTERACTION
    Cervantes, Geovanny
    Cervantes, Wilmer
    Ahmed, Muhammad Umer
    Jesmajian, Stephen
    CHEST, 2024, 166 (04) : 2179A - 2180A
  • [48] Health-related quality of life in chronic liver disease: The impact of type and severity of disease
    Younossi, ZM
    Boparai, N
    Price, LL
    Kiwi, ML
    McCormick, M
    Guyatt, G
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (07): : 2199 - 2205
  • [49] Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments
    Santamaria, Fiorenza
    Roberto, Michela
    Buccilli, Dorelsa
    Di Civita, Mattia Alberto
    Giancontieri, Paola
    Maltese, Giulia
    Nicolella, Francesco
    Torchia, Andrea
    Scagnoli, Simone
    Pisegna, Simona
    Barchiesi, Giacomo
    Speranza, Iolanda
    Botticelli, Andrea
    Santini, Daniele
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 200
  • [50] The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy
    Guven, Deniz C.
    Kavgaci, Gozde
    Aktepe, Oktay H.
    Yildirim, Hasan C.
    Sahin, Taha K.
    Aksoy, Sercan
    Erman, Mustafa
    Kilickap, Saadettin
    Yalcin, Suayib
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (04) : 785 - 793